Equity
Boston Scientific·Balance Sheet Statement·8 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities and stockholders' equity | $37.1B | $38.1B | $39.4B | $40.1B | $41.6B | $42.7B | $43.7B | $44.4B |
| Total stockholders' equity | $20.4B | $20.7B | $21.8B | $22.2B | $22.4B | $23.4B | $24.2B | $25.9B |
| Additional paid-in capital | $20.8B | $21B | $21.1B | $21.1B | $21.2B | $21.4B | $21.5B | $21.6B |
| Retained earnings | $1.6B | $2.1B | $2.7B | $3.3B | $4.1B | $4.9B | $5.6B | $6.9B |
| Treasury Stock, Value | $2.3B | $2.3B | $2.3B | $2.3B | $2.3B | $2.3B | $2.3B | $2.3B |
| Accumulated other comprehensive income (loss) | $164M | -$128M | $275M | -$28M | -$722M | -$689M | -$610M | -$398M |
| Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M |
| Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |